We and others have shown that high concentrations (> 100 μM) of propranolol alone are required to reduce hemangiosarcoma and angiosarcoma cell viability (32, 33), suggesting that the previously reported effects of propranolol on reducing tumor cell survival are not mediated by β-AR antagonism. This evidence concerns the gene ADRB2 and neoplasm.